Nivolumab-Induced Granuloma Annulare

Immune-checkpoint inhibitors (ICIs) such as pembrolizumab and nivolumab have transformed oncologic therapeutic modalities. By disrupting tumor-induced immunosuppression, ICIs facilitated effective treatment of numerous malignancies, including metastatic melanoma; however, due to the ensuing disturbance immune system, various immune-mediated adverse reactions been reported with ICI therapy. We present a case nivolumab-induced granuloma annulare in 54-year-old woman. Recognition association between therapy cutaneous is crucial ensure accurate diagnosis adequate patients taking ICIs.